Chemotherapy targeted to cancers through tumoral hormone receptors (Q35879365)

10 August 2017

1 reference

title

Chemotherapy targeted to cancers through tumoral hormone receptors (English)

1 reference

10 August 2017

1 reference

1

Andrew V Schally

1 reference

10 August 2017

Attila Nagy

2

1 reference

10 August 2017

publication date

1 September 2004

1 reference

Trends in Endocrinology and Metabolism

10 August 2017

published in

1 reference

10 August 2017

volume

15

1 reference

10 August 2017

issue

7

1 reference

10 August 2017

page(s)

300-310

1 reference

Drug-targeting strategies in cancer therapy

10 August 2017

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Somatostatin analogs in the diagnosis and treatment of cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Therapeutic cancer targeting peptides

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Growth Inhibition of Human Ovarian Cancers by Cytotoxic Analogues of Luteinizing Hormone-Releasing Hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Peptide receptors as molecular targets for cancer diagnosis and therapy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Targeted toxin therapy for the treatment of cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Hypothalamic hormones and cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Somatostatin, its receptors and analogs, in lung cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Somatostatin and its receptor family

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Human ovarian cancers express somatostatin receptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Identifiers

DOI

10.1016/J.TEM.2004.07.002

1 reference

10 August 2017

1 reference